For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow. Now, that routine is changing. The FDA has approved the first and only once-weekly insulin ever approved for adults with type 2 diabetes in the United States. This is not a minor update to an existing drug. It’s the first entirely new class of insulin to reach U.S. patients in more than two decades. Instead of injecting insulin every single day, people with type 2 diabetes using the drug Awigli will only need one shot a week, on the same day every week. That means reducing 365 injections a year down to just 52. For anyone who has ever felt the weight of that daily ritual and the anxiety of forgetting, this approval represents something much bigger than a dosing schedule — it represents relief. Fewer needles, simpler scheduling, less hassle — all those things matter to diabetics. It’s not a new drug — it’s a new way of keeping people healthy, one week at a time.
